Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced a delay in the dispatch of a key document related to its proposed privatization of Henlius by way of merger. The delay is due to the requirement of additional time to fulfill pre-conditions, such as obtaining governmental approvals. Investors are cautioned that the merger’s completion is contingent upon satisfying these conditions.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
